About Genomenon

Genomenon means “born out of need” in ancient Greek, which perfectly describes Genomenon’s beginnings.

In his clinical practice and genomic research, co-founder Dr. Mark Kiel was frustrated with the painfully slow and time-consuming process of manual curation. Interpretation of genomic data resulting from next-generation DNA sequencing (NGS) was inefficient and error-prone due to the manual effort required to search and analyze the rapidly growing body of medical literature for disease-related genes and variants.

Genomenon was founded to address this pressing need for faster, more comprehensive variant interpretation by combining expert curation with unique machine learning methods designed to keep up with the pace of new publications and present the most relevant information to researchers.

Mark found like-minded experts dedicated to connecting patient DNA data with the billions of dollars worth of medical research that was previously impossible to organize at scale, and too challenging to interpret quickly and accurately for clinical genomics.

The Genomenon team built the Mastermind Genomic Search Engine, which contains all the disease-gene-variant-phenotype-therapy relationships found across the scientific literature. The technology developed to accomplish this feat is revolutionizing the way genetic and cancer diagnoses and discoveries are made. Mastermind makes it easy to get rapid insight into relevant literature for clinical decision-making, genomic research, and pharmaceutical drug discovery.

Today, co-founders Kiel and Steve Schwartz continue to drive the scientific and technological development of Mastermind, which now empowers scientists and researchers at pharmaceutical companies, clinical labs, and universities to more thoroughly understand diseases at a molecular level. Thousands of doctors in over 100 countries are using Mastermind to rapidly connect their patient’s variants with the published genomic research to more effectively treat cancer patients and diagnose babies with rare diseases.

Genomenon is headquartered in Ann Arbor, Michigan.